BACKGROUND: Using autologous cryopreserved mononuclear cells (MNCs) for extracorporeal photochemotherapy (ECP) offers several advantages, such as treating patients from geographically distant care centers or maintaining ECP schedule while dramatically reducing number of apheresis sessions. We previously reported that cryopreserved cells retain their immunomodulatory properties when exposed to UVA and psoralen. To date, there are no clinical data on the use of cryopreserved MNCs for ECP ("cryo-ECP"). CASE REPORTS: Three patients were treated by cryo-ECP for refractory dermatomyositis, juvenile localized scleroderma, and acute graft-versus-host disease. For the first two patients, cryo-ECP aimed to reduce the number of apheresis sessions. Each cell product was split into three equal fractions: one was infused, and the other two were frozen for later infusion. The third patient was referred to our center from a hospital 700 km away. Fifteen apheresis procedures were performed during his stay: 12 were immediately treated and infused while three were cryopreserved. After discharge, the three cryopreserved bags were thawed, ECP-treated, and then sent back to the patient. CONCLUSION: In all three patients, cryo-ECP was safe and feasible. These cases illustrate promising clinical applications of the technique, opening perspectives for making ECP much more acceptable to patients while extending its indications.
BACKGROUND: Using autologous cryopreserved mononuclear cells (MNCs) for extracorporeal photochemotherapy (ECP) offers several advantages, such as treating patients from geographically distant care centers or maintaining ECP schedule while dramatically reducing number of apheresis sessions. We previously reported that cryopreserved cells retain their immunomodulatory properties when exposed to UVA and psoralen. To date, there are no clinical data on the use of cryopreserved MNCs for ECP ("cryo-ECP"). CASE REPORTS: Three patients were treated by cryo-ECP for refractory dermatomyositis, juvenile localized scleroderma, and acute graft-versus-host disease. For the first two patients, cryo-ECP aimed to reduce the number of apheresis sessions. Each cell product was split into three equal fractions: one was infused, and the other two were frozen for later infusion. The third patient was referred to our center from a hospital 700 km away. Fifteen apheresis procedures were performed during his stay: 12 were immediately treated and infused while three were cryopreserved. After discharge, the three cryopreserved bags were thawed, ECP-treated, and then sent back to the patient. CONCLUSION: In all three patients, cryo-ECP was safe and feasible. These cases illustrate promising clinical applications of the technique, opening perspectives for making ECP much more acceptable to patients while extending its indications.
Authors: A Sauret; N Rabiau; E Rochette; V Grèze; P Halle; M Ouachée; J-H Dalle; E Seror; D Serraz; K Yakouben; D Adjaoud; A Pagnier; A Marie-Cardine-Bobbia; C Oudot; C Curtillet; M Poirée; J Kanold; E Merlin Journal: Bone Marrow Transplant Date: 2016-02-08 Impact factor: 5.483
Authors: Marie Laulhé; Sylvie Lefebvre; Delphine Le Broc-Ryckewaert; Maxime Pierre; Aurélie Ferry; Bruno Delorme Journal: PLoS One Date: 2019-03-01 Impact factor: 3.240
Authors: Jennifer Schneiderman; Longhui Qiu; Xin Yi Yeap; Xin Kang; Feibo Zheng; Junsheng Ye; Yan Xie; Jiao-Jing Wang; Yuvaraj Sambandam; James Mathew; Lin Li; Joseph Leventhal; Richard L Edelson; Zheng Jenny Zhang Journal: Sci Rep Date: 2022-05-04 Impact factor: 4.996